Parkwalk Advisors

Brainomix Limited, established in 2010 as a spin-out from the University of Oxford, develops advanced imaging biomarkers and software solutions aimed at enhancing clinical decision-making for neurological and cerebrovascular disorders. The company's flagship product, e-Stroke, employs state-of-the-art artificial intelligence algorithms to automate the interpretation of brain scans, specifically for acute ischemic stroke patients. This tool assists physicians in identifying and quantifying early stroke damage, thereby facilitating timely and informed treatment decisions. In addition to e-Stroke, Brainomix offers other software products such as e-ASPECTS, which automates the Alberta Stroke Program Early CT Score, and e-CTA, which standardizes the assessment of large vessel occlusion locations. These innovative solutions address the critical need for rapid and consistent evaluations of brain CT scans, ultimately optimizing patient outcomes and ensuring that stroke patients receive appropriate care in a timely manner. The company is headquartered in Oxford, United Kingdom.

PervasID is developing a high reliability, wide area passive RFID system with the potential to provide location capability based on the EPC Class1 Gen2 standard. Spun out from research activity in the Engineering Department at the University of Cambridge, the technology is now successfully deployed in several field trials.

Ikarovec is a gene therapy company focused on developing early-stage assets for the treatment of common eye diseases, particularly diabetic macular edema. The company aims to address multiple disease targets and pathways, including dry-form age-related macular degeneration, neovascular (wet-form) age-related macular degeneration, and ocular hypertension. By targeting these conditions, Ikarovec seeks to provide effective treatments that restore sight and prevent blindness in patients.

PhoreMost Limited is a drug discovery company based in Cambridge, United Kingdom, focused on identifying new druggable targets for cancer and other unmet diseases. Since its incorporation in 2014, the company has developed Site-Seeker, a platform that uncovers cryptic druggable sites within the human genome and connects them to therapeutic functions in live-cell contexts. This innovative approach allows PhoreMost to design small molecule drugs based on functionally validated protein fragments. By collaborating with a global network of academic and industrial partners, the company aims to bring novel targeted therapies to market more efficiently, ultimately benefiting patients through cost savings and the development of first-in-class drug discovery programs for potential licensing to pharmaceutical companies.

xwatts is an intelligent energy management system that helps commercial buildings reduce costs and emissions.

Psyomics is engaged in the development of proteomic diagnostics aimed at improving the early diagnosis and treatment outcomes for individuals with neuropsychiatric disorders. The company offers a web-based assessment triage system that integrates digital profiling with advancements in biological research to enhance diagnostic accuracy. This approach assists primary care practitioners in effectively managing their patients' mental health needs by replicating a psychiatric assessment at the initial point of contact. By doing so, Psyomics facilitates improved recovery outcomes for patients suffering from mental health disorders.

Oxford Endovascular is focused on developing an innovative medical device for the treatment of brain aneurysms. The company's technology employs a laser-cut metal alloy with shape-memory properties, which can be inserted into a patient's brain via a catheter. Once in place, the device expands into a tiny mesh tube, known as a flow diverter, that conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, facilitating its healing and reducing the risk of rupture. By utilizing advanced origami engineering, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for those affected by intracranial aneurysms.

Adsilico redefines medical device innovation.

Echopoint Medical Ltd is a medical device company specializing in the development of optical-fibre based sensors aimed at enhancing the diagnosis and treatment of cardiovascular diseases. Originating as a spin-out from University College London, the company focuses on integrating innovative sensing modalities into minimally invasive medical procedures. These advanced devices offer unprecedented imaging and sensing capabilities, which help healthcare providers improve patient outcomes while reducing costs and complications associated with cardiac surgeries. By leveraging breakthroughs in fibre optic sensor technology, Echopoint Medical addresses critical unmet needs for patients and clinicians alike.

Building the Workforce of Tomorrow, Today. We help you understand your current workforce and leverage data-driven technology to attract, screen and retain top talent; ensuring that you build diverse and productive teams in the fairest way possible. Everything we do plugs seamlessly into your ATS and CRM, do you don't need to change your processes.

Koalaa offers comfy, soft prosthetic arms and personalized support, for babies, kids, and adults. Koalaa's mission is to make prostheses comfortable and affordable to anyone on the planet.

Wayland Additive Limited is a West-Yorkshire based company pushing the boundaries of electron beam 3D printing. Wayland’s goal is to develop, manufacture and sell metal Additive Manufacturing (“AM” – 3D printing) machines to industrial end-users such as major players in the aerospace and medical industries.

Albus Health, a startup emerging from the University of Oxford, has created an intelligent nocturnal monitoring platform designed for personalized home use. This system facilitates passive, contactless, and objective monitoring of various symptoms and environmental metrics, making it particularly useful for assessing nocturnal conditions. The platform has been successfully commercialized and is currently employed by leading pharmaceutical companies to monitor nocturnal symptoms during clinical trials. Additionally, it has the capability to predict respiratory emergencies, thus enhancing patient safety and outcomes.

Proxisense specializes in developing advanced proximity sensors and fluid contamination monitoring systems, utilizing eddy current technology to enhance the performance of complex rotating equipment. Their proximity sensors are particularly effective in real-time health monitoring of turbine blades, which can prolong component lifespans and minimize maintenance and downtime costs. The company primarily targets the power and aerospace industries, collaborating with major original equipment manufacturers to address critical challenges. Additionally, Proxisense's fluid contamination systems offer reliable, real-time monitoring of fuels and lubricants, which is essential for transportation assets operating in diverse environments. By detecting contamination early, Proxisense helps reduce damage to components, maintain optimal operating conditions, and prevent potential system failures.

Nu Quantum Ltd is a company focused on developing quantum photonics hardware and infrastructure essential for scaling quantum computers. Founded in 2018 and based in Cambridge, United Kingdom, the company specializes in creating solutions that interconnect quantum computing cores into large distributed clusters. Its offerings include photon sources and detectors, as well as systems for quantum cryptography that enable secure key exchanges. Nu Quantum is also engaged in producing nano-engineered materials that facilitate light generation at the quantum level and ultra-sensitive light detection. By partnering with leading quantum computing companies, governments, and research institutions, Nu Quantum aims to advance the development of entangled qubit networks and accelerate the creation of multi-core quantum supercomputers and quantum data centers.

Mogrify has developed a proprietary suite of technologies aimed at advancing patient care through innovative in vivo reprogramming therapies. The company's platforms, MOGRIFY and epiMOGRIFY, utilize a systematic big-data approach to direct cellular reprogramming, leveraging next-generation sequencing and gene regulatory data to predict the necessary transcription and growth factors for generating any target human cell type from various sources. This technology enhances existing stem cell programming methods or allows for direct transdifferentiation between mature cell types. Mogrify focuses on creating functional cell types for applications in ophthalmology, otology, and other degenerative diseases, addressing critical challenges related to efficacy, safety, and scalability in cell therapy. Positioned within a regenerative medicine market projected to reach $150 billion by 2028, Mogrify is commercializing its technology through in vivo therapy development, co-development partnerships, and exploration of additional therapeutic and non-therapeutic applications.

Fresh Check is a simple sticker that you put inside the packaging of food that changes colour when your food has actually gone off, not when the use-by date says so.

Phasecraft is a UK-based company founded in 2018 that develops quantum software aimed at enhancing the practical application of quantum computing. The firm focuses on creating algorithms for quantum information processors, including intermediate-scale devices and quantum computers. By leveraging its expertise in quantum science and engineering, Phasecraft addresses significant industrial challenges, such as optimizing key processes and exploring new materials. The company's software supports clients in investigating innovative quantum materials and developing advanced technologies, including batteries and efficient solar cells. Through its work, Phasecraft aims to facilitate breakthrough scientific discoveries and enable entrepreneurs to tackle pressing global issues more effectively.

Entia is a medical technology company that specializes in improving access to blood tests. Its featured products include Aptus, designed for haemoglobin and haematocrit and Affinity, designed for people with cancer to monitor their blood counts at home. The company is a multidisciplinary team spanning design, engineering, quality assurance, business development, and innovation.

RoboK is a computer vision startup based in Cambridge, United Kingdom, founded in 2017. The company specializes in designing and developing simultaneous localization and mapping (SLAM) algorithms and advanced 3D sensing technologies tailored for automotive and industrial applications, including autonomous driving and machine automation. RoboK focuses on enhancing safety and performance in industrial workplaces through innovative, privacy-preserving technology that optimizes the capabilities of existing CCTV systems. By transforming visual data from large-scale transport and logistics infrastructures into actionable insights, RoboK collaborates with major operators in critical sectors to deliver enhanced object detection, classification, and tracking. The company aims to maximize the value of visual data, turning passive surveillance systems into proactive tools for efficiency and safety.

Cambridge Touch Technologies, Ltd. specializes in developing innovative touch technology for smart devices, including smartphones, tablets, and applications in automotive and industrial sectors. The company's flagship offering, UltraTouch, integrates a proprietary artificial intelligence engine with advanced piezoelectric force film to create an all-in-one touch and force sensor architecture. This technology not only enhances the user experience by enabling three-dimensional touch capabilities but also offers superior functionality at a lower cost. UltraTouch is designed to be scalable, accommodating various device sizes and shapes, including curved and foldable formats, thereby ensuring versatility in application across multiple industries.

Signaloid is a technology company that offers a cloud-based computing platform designed to track uncertainties in data inputs and their effects on software outputs. Its advanced hardware and software technologies cater to a range of applications, including materials modeling, autonomous systems, computational finance, machine learning, and quantum computing. By providing tools that allow clients to assess the quality of decisions made through algorithms and data, Signaloid helps organizations meet regulatory requirements, optimize costs, and enhance safety outcomes.

PharmEnable has developed a rapid and cost effective way to identify better chemical starting points to drive the discovery of vital new medicines.

DefiniGEN Limited specializes in providing human cell products for the life science and drug discovery sectors, focusing on applications in predictive toxicology, metabolic diseases, and regenerative medicine. The company’s product offerings include wild-type human hepatocytes and pancreatic cells for research in diabetes, alongside disease-modelled cells for conditions such as glycogen storage disease and hypercholesterolemia. DefiniGEN leverages its advanced stem cell production platform, developed at the University of Cambridge, to create high-functionality cell types that enhance drug discovery processes. The company also offers a range of services, including custom cell production, gene-editing, and diabetes compound profiling, catering primarily to pharmaceutical companies. Established in 2011 and based in Cambridge, UK, DefiniGEN builds on its strong intellectual property foundation, including expertise in induced pluripotent stem cell technology.

Carbometrics is a specialized chemistry company focused on the design, synthesis, and derivatization of highly selective carbohydrate-binding molecules. Building on over 20 years of research led by Professor Anthony Davis at the University of Bristol, the company aims to develop a robust and accurate glucose sensing platform. This technology is intended to create a market-leading Continuous Glucose Monitoring (CGM) solution, helping individuals with diabetes manage their condition more effectively. Carbometrics was established following the founders' successful sale of their previous company, Ziylo, to Novo Nordisk, which is utilizing a similar platform for the development of smart insulins.

Xampla Ltd is a cleantech company based in Cambridge, United Kingdom, that specializes in developing plant protein-based materials as sustainable alternatives to traditional plastics and microplastics. Founded in 2018, Xampla produces a variety of products, including microcapsules, films, coatings, and beads, which are designed for use in sectors such as food, cosmetics, household products, animal feed, packaging, and medical applications. All materials are biodegradable and biocompatible, made without synthetic ingredients, allowing clients to create environmentally friendly products that minimize pollution.

Wayland Additive Limited is a West-Yorkshire based company pushing the boundaries of electron beam 3D printing. Wayland’s goal is to develop, manufacture and sell metal Additive Manufacturing (“AM” – 3D printing) machines to industrial end-users such as major players in the aerospace and medical industries.

AccelerComm Ltd specializes in providing Forward Error Correction (FEC) solutions for various communication markets, including mobile handsets, base stations, and satellite standards. Founded in 2016 and based in Southampton, United Kingdom, the company focuses on enhancing the performance of next-generation wireless communications, addressing challenges such as noise, interference, and weak signal strength. Its product offerings include a range of encoding and decoding technologies, such as Polar, Turbo, and LDPC (Low-Density Parity-Check) decoders, specifically designed to meet 3GPP compliance. By delivering innovative semiconductor IP-core products, AccelerComm aims to facilitate optimal performance in digital communications while supporting the evolving needs of the industry.

OSSTEC specializes in advanced technology for orthopedic applications, focusing on the development of metal 3D printed bone healing implants. These innovative implants are designed to mimic the natural structure of bone, addressing the high failure rates associated with traditional orthopedic solutions. By stimulating long-term bone growth, OSSTEC's products aim to improve the quality of life for patients suffering from conditions such as osteoarthritis, enabling them to remain active and pain-free. The company's commitment to enhancing bone healing technology positions it as a key player in the orthopedic market.

TextMine is a developer of an AI-powered knowledge base designed to manage and streamline business-critical documents, including invoices, payslips, tender documents, compliance reports, and contracts. Utilizing patented knowledge graph technology, the platform enhances the usability and searchability of contract data, consolidating information into a single operational layer. This approach facilitates proactive decision-making and improves data transparency, allowing for more scalable and uniform document creation. By implementing TextMine's solutions, organizations can achieve significant savings in time and costs while minimizing risk and enhancing compliance.

NoBACZ is developing an innovative precision bandaging platform aimed at enhancing wound care management for both veterinary and human applications. The company focuses on creating rapid set liquid barriers that serve as sterile, antimicrobial, and biodegradable wound care products. These bandages can be customized to accommodate various wound types, allowing healthcare professionals to efficiently address deep wounds while minimizing the risk of infections that can arise from traditional bandaging methods. By optimizing wound care, NoBACZ seeks to improve treatment outcomes in medical and veterinary settings.

Mind Foundry Limited, headquartered in Oxford, United Kingdom, was founded in 2015 and specializes in developing software that helps organizations extract valuable insights from their data. As a spin-off from Oxford University, Mind Foundry combines innovation with usability through its Responsible AI platform, which addresses significant real-world challenges across various sectors, including insurance, infrastructure, and defense. The company’s technologies apply machine learning and advanced algorithmic modeling to enhance decision-making and problem-solving capabilities for clients. Founded by noted AI and machine learning experts, Mind Foundry aims to foster collaboration between humans and AI, promoting responsible and transparent AI usage while tackling pressing issues such as insurance fraud detection and complex signal processing.

Zomp is a provider of consumer electronics.

Symetrica Ltd. specializes in the development and commercialization of integrated radiation detection and identification technologies tailored for government and custom organizations across the globe. Founded in 2002 and headquartered in Southampton, United Kingdom, with an additional office in Maynard, Massachusetts, the company offers advanced systems that enhance security operations in various sectors, including military and homeland security. Its product range features handheld and backpack-mounted sensors, vehicle-based detectors, and drive-through scanners, all utilizing machine learning to improve threat identification and response. Symetrica's technology is also applicable in fields such as medical diagnostics, geophysical research, and space exploration.

Quantum Motion Technologies is focused on developing universal quantum computers utilizing silicon-based, CMOS-compatible processes. The company aims to address key challenges in quantum computing, such as fault tolerance and qubit redundancy, by creating scalable architectural technologies. By leveraging complementary metal-oxide semiconductor processing, Quantum Motion strives to achieve greater qubit density, enabling the construction of large-scale quantum systems. This approach not only enhances the performance of quantum computers but also assists clients in the quantum technology sector in overcoming significant errors and critical challenges in quantum information processing.

Qkine Ltd, founded in 2016 and based in Cambridge, United Kingdom, specializes in manufacturing high-purity, animal-free growth factors, cytokines, and complex proteins. The company leverages proprietary protein production processes developed at the University of Cambridge, along with advanced protein engineering techniques, to create unique products that address key challenges in the stem cell, organoid, regenerative medicine, and cultivated meat sectors. Qkine's product line includes innovative offerings such as tag-free thermostable FGF-2, the first animal-free TGF beta 1 for chemically defined stem cell media, and animal-free HGF. With an active research and development pipeline and a commitment to quality, Qkine is ISO 9001:2015 certified, ensuring that it provides high-purity, bioactive proteins to support scientific advancements in life sciences.

Diffblue Limited, based in Oxford, United Kingdom, specializes in artificial intelligence software that automates various coding tasks, primarily focusing on enhancing Java development through automated testing solutions. Founded in 2016 as a spin-out from the AI research group at Oxford, Diffblue's technology autonomously generates unit tests, which helps developers save time and ensure software robustness. The software not only creates fully formed tests guaranteed to compile and run, but also identifies and fixes bugs, refactors code, and maintains regression tests. By providing insights into test coverage, code testability, and complexity, Diffblue aims to transform the software development process, making it more efficient and less error-prone.

Enhanc3D Genomics is a functional genomics company that focuses on understanding the three-dimensional organization of DNA and its implications for health and disease. The company has developed the GenLink3D platform, which facilitates the analysis of genetic variations and gene function by providing high-resolution profiles of genome folding. This technology allows researchers to examine the effects of mutations on distant genes and their roles in disease progression. By offering insights into gene interactions and enhancer activity, Enhanc3D Genomics aims to support the advancement of novel drug development in areas with significant unmet medical needs.

Opsydia is set to disrupt a number of industries by its ability to create practically invisible structures inside transparent materials. Permanent and inimitable serial numbers, images or cryptographic data can be laser-written without compromising the integrity of the material or modifying its surface. Material applications include diamond, glass and polymers

PervasID is developing a high reliability, wide area passive RFID system with the potential to provide location capability based on the EPC Class1 Gen2 standard. Spun out from research activity in the Engineering Department at the University of Cambridge, the technology is now successfully deployed in several field trials.

MoA Technology Ltd. is a plant genetics company based in Leeds, United Kingdom, that was incorporated in 2017. It was spun out from the University of Oxford and focuses on developing innovative agricultural technologies aimed at enabling farmers to produce healthy food through sustainable crop systems. The company leverages research led by Professor Liam Dolan to discover new methods that enhance agricultural productivity while promoting sustainability.

Concr is a techbio company focused on enhancing cancer treatment by predicting patient responses to various therapies. Utilizing methods from astrophysics, Concr's innovative approach allows for iterative learning from diverse data sources throughout a drug's clinical journey, resulting in accurate multi-modal tumor models without relying on extensive data sets. Its cloud-native platform, FarrSight®, enables researchers to simulate clinical trials, predict therapeutic responses and biomarkers, and conduct standard bioinformatics analyses. This technology aims to identify optimal treatments for individual patients, reduce treatment resistance, and facilitate personalized cancer management. Headquartered in London with a subsidiary in Brisbane, Australia, Concr is backed by several investors, including the University of Cambridge Enterprise and Oncology Ventures.

Ceryx Medical Limited specializes in the development and manufacturing of bio-electronic devices that utilize patented chip technology to replicate Central Pattern Generators (CPGs) within the human body. Founded in 2016 and based in Bath, United Kingdom, the company’s innovative devices aim to manage various autonomic and rhythmic bodily processes, including peristalsis, heart rate, and walking. Ceryx Medical focuses on restoring normal function in these processes when they are disrupted due to disease or injury, offering potential therapeutic solutions for conditions such as heart failure.

GripAble Ltd. designs and develops digital therapy devices aimed at improving rehabilitation for individuals with movement impairments such as stroke, arthritis, cerebral palsy, and trauma. Founded in 2017 and based in London, the company offers a portable, wireless handgrip device that connects to a mobile application. This application allows users to engage with therapy games while providing assessment and training for hand and arm functions. GripAble's innovative approach focuses on making therapy more accessible and engaging for patients, enabling them to practice essential daily tasks in a fun and motivating way. By combining hardware and software, GripAble addresses the needs of over 500 million people worldwide who face challenges with arm mobility, facilitating self-training both in clinical settings and at home.

NK:IO is a biotechnology company focused on advancing natural killer cell-mediated immunotherapy, particularly in the realm of cancer treatment. The company specializes in developing innovative cell therapies and small molecule therapeutics designed to enhance the effectiveness of cancer targeting for physicians. By leveraging cutting-edge research and technology, NK:IO aims to improve treatment outcomes for patients facing cancer.

SERG Technologies is re-defining the way we interact with technology by creating reliable and functional wearables that can be used for activity tracking, monitoring health and fitness, and gesture recognition for smart devices. Our unique sensors detect tiny, subconscious movements that indicate a wearer’s intent, we turn these into control signals for everything from TV’s to smart prosthetics, resulting in almost instant response times. We are also developing new tools to allow Parkinson's patients to track their symptoms, providing vital new information to their doctors, leading to long term improvements to the efficacy their treatment. SERG was founded to make the gesture control of technology accessible for everyone and easier to use than ever before.

BibliU Ltd is a software company headquartered in London, UK, with an additional office in New York, that specializes in providing a digital platform for accessing textbooks and educational resources. Founded in 2014, BibliU enables students to access textbooks and other course materials online through various devices, allowing for flexible study options. The company's platform offers features such as offline support, a discovery search tool, and tools for synchronized highlights and comments, enhancing the learning experience and productivity. BibliU collaborates with numerous publishers and open educational resource providers to offer a vast array of digital content, making academic materials more accessible and affordable for colleges and universities.

Sano Genetics Limited is a health technology company based in Cambridge, United Kingdom, that operates a user-centric genetic data-sharing platform. Founded in 2017, the company enables individuals to contribute their genetic and health data for research purposes, thereby advancing personalized medicine and scientific understanding. It provides researchers with tools to analyze user-consented data, facilitating recruitment for studies and clinical trials. The platform supports research on a variety of genetic conditions and human traits, including common disorders such as eczema, diabetes, and depression, as well as rare diseases like muscular dystrophy. By allowing participants to share their genetic information, Sano Genetics aims to enhance the development of new treatments and cures in the field of medicine.

Semarion is a spin-out from the Cavendish Laboratory at the University of Cambridge, specializing in drug discovery and cell microcarrier technology. The company aims to enhance the process of drug screening by utilizing innovative materials and techniques from the microchip industry combined with cell biology. Its platform features ultra-miniaturized, magnetically steerable microcarriers designed to support small colonies of cells, which facilitates advanced assaying workflows and new experimental approaches. This technology is particularly focused on identifying GPCR-targeting oncology drugs, addressing significant gaps in medical needs and accelerating the pace of drug development.

Paragraf Ltd. is a UK-based company specializing in the development of graphene technology and the production of two-dimensional materials. Established in 2015, Paragraf focuses on creating graphene-based electronic devices, including magnetic sensors and biosensors, that are designed to enhance technological performance in various sectors such as electronics, energy, research, automation, and healthcare. The company employs contamination-free technology to ensure the production of high-purity graphene products that meet commercial quality standards. Paragraf's innovations aim to optimize process control, improve quality assurance, and facilitate monitoring of environmental and health conditions, thereby contributing to advancements in green energy generation and other critical applications.

Barocal specializes in innovative cooling technology aimed at addressing low-carbon refrigeration needs. The company has developed a system that utilizes materials capable of significant thermal changes when pressure is applied or removed. This unique approach enhances energy efficiency while ensuring a zero greenhouse warming impact, particularly in the commercial food and drink refrigeration sector. By implementing Barocal's technology, clients can effectively reduce their indirect emissions of greenhouse gases, contributing to a more sustainable environment.

Bramble Energy Ltd. is a London-based company that specializes in the design, development, and manufacture of printed circuit board (PCB) fuel cells, specifically proton exchange membrane fuel cells (PEMFCs). Incorporated in 2015, it leverages the capabilities of the global PCB industry to produce high-performance, cost-effective fuel cell stacks. The company's product lineup includes modular PCBFC stacks, ranging from 20 W to 5 kW, as well as custom-designed solutions. Bramble Energy serves various sectors, including stationary, portable, and automotive applications, aiming to provide gigawatts of fuel cell hardware. By utilizing innovative manufacturing methods and materials, the company enables clients to reduce energy consumption and lower their carbon footprints.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

Sano Genetics Limited is a health technology company based in Cambridge, United Kingdom, that operates a user-centric genetic data-sharing platform. Founded in 2017, the company enables individuals to contribute their genetic and health data for research purposes, thereby advancing personalized medicine and scientific understanding. It provides researchers with tools to analyze user-consented data, facilitating recruitment for studies and clinical trials. The platform supports research on a variety of genetic conditions and human traits, including common disorders such as eczema, diabetes, and depression, as well as rare diseases like muscular dystrophy. By allowing participants to share their genetic information, Sano Genetics aims to enhance the development of new treatments and cures in the field of medicine.

Paragraf Ltd. is a UK-based company specializing in the development of graphene technology and the production of two-dimensional materials. Established in 2015, Paragraf focuses on creating graphene-based electronic devices, including magnetic sensors and biosensors, that are designed to enhance technological performance in various sectors such as electronics, energy, research, automation, and healthcare. The company employs contamination-free technology to ensure the production of high-purity graphene products that meet commercial quality standards. Paragraf's innovations aim to optimize process control, improve quality assurance, and facilitate monitoring of environmental and health conditions, thereby contributing to advancements in green energy generation and other critical applications.

Diffblue Limited, based in Oxford, United Kingdom, specializes in artificial intelligence software that automates various coding tasks, primarily focusing on enhancing Java development through automated testing solutions. Founded in 2016 as a spin-out from the AI research group at Oxford, Diffblue's technology autonomously generates unit tests, which helps developers save time and ensure software robustness. The software not only creates fully formed tests guaranteed to compile and run, but also identifies and fixes bugs, refactors code, and maintains regression tests. By providing insights into test coverage, code testability, and complexity, Diffblue aims to transform the software development process, making it more efficient and less error-prone.

Cambridge Touch Technologies, Ltd. specializes in developing innovative touch technology for smart devices, including smartphones, tablets, and applications in automotive and industrial sectors. The company's flagship offering, UltraTouch, integrates a proprietary artificial intelligence engine with advanced piezoelectric force film to create an all-in-one touch and force sensor architecture. This technology not only enhances the user experience by enabling three-dimensional touch capabilities but also offers superior functionality at a lower cost. UltraTouch is designed to be scalable, accommodating various device sizes and shapes, including curved and foldable formats, thereby ensuring versatility in application across multiple industries.

Pathfinder Medical is focused on creating a novel electronic guidance system that facilitates minimally invasive connections between blood vessels. This innovative catheter-based technology is designed specifically for treating kidney failure, allowing for vascular access creation that can be performed outside of traditional operating rooms. The system aims to improve the reliability of hemodialysis access for patients, addressing a significant market opportunity valued at £1.6 billion annually. By reducing the likelihood of failure, Pathfinder Medical’s solution enhances treatment options for patients requiring dialysis, showcasing its potential impact in the healthcare sector.

Psyomics is engaged in the development of proteomic diagnostics aimed at improving the early diagnosis and treatment outcomes for individuals with neuropsychiatric disorders. The company offers a web-based assessment triage system that integrates digital profiling with advancements in biological research to enhance diagnostic accuracy. This approach assists primary care practitioners in effectively managing their patients' mental health needs by replicating a psychiatric assessment at the initial point of contact. By doing so, Psyomics facilitates improved recovery outcomes for patients suffering from mental health disorders.

Fuel3D is a developer of advanced 3D imaging technology that offers a handheld 3D scanning system capable of capturing high-resolution shape and color information. Initially created for the medical imaging sector at Oxford University, this point-and-shoot scanner is designed to facilitate the rapid generation of 3D images for diverse applications, including art, animation, and game development. The innovative technology combines pre-calibrated stereo cameras with photometric imaging, allowing users to quickly and affordably produce detailed 3D representations, which are typically expensive and time-consuming to create. Fuel3D aims to make high-quality 3D scanning accessible to a broader audience, including independent developers and artists. The company is led by CEO Stuart Mead, who has extensive experience in global technology ventures, and continues to adapt its technology for various markets beyond its original medical focus.

Brainomix Limited, established in 2010 as a spin-out from the University of Oxford, develops advanced imaging biomarkers and software solutions aimed at enhancing clinical decision-making for neurological and cerebrovascular disorders. The company's flagship product, e-Stroke, employs state-of-the-art artificial intelligence algorithms to automate the interpretation of brain scans, specifically for acute ischemic stroke patients. This tool assists physicians in identifying and quantifying early stroke damage, thereby facilitating timely and informed treatment decisions. In addition to e-Stroke, Brainomix offers other software products such as e-ASPECTS, which automates the Alberta Stroke Program Early CT Score, and e-CTA, which standardizes the assessment of large vessel occlusion locations. These innovative solutions address the critical need for rapid and consistent evaluations of brain CT scans, ultimately optimizing patient outcomes and ensuring that stroke patients receive appropriate care in a timely manner. The company is headquartered in Oxford, United Kingdom.

Wayland Additive Limited is a West-Yorkshire based company pushing the boundaries of electron beam 3D printing. Wayland’s goal is to develop, manufacture and sell metal Additive Manufacturing (“AM” – 3D printing) machines to industrial end-users such as major players in the aerospace and medical industries.

Charco Neurotech is a medical technology company focused on developing non-invasive wearable devices aimed at improving the quality of life for individuals with Parkinson's disease. The company's primary product is designed to modulate sensory dysfunction, which assists users in enhancing their movement speed. By providing a solution that allows people with Parkinson's to maintain a more normal lifestyle, Charco Neurotech addresses significant challenges faced by this population, ultimately contributing to better overall health and well-being.

Carbon Re is a climate technology company focused on utilizing artificial intelligence to decarbonize energy-intensive industries such as cement, steel, and glass, which collectively contribute over 20% of global carbon emissions. The company has developed the Delta Zero platform, which leverages deep learning to facilitate the rapid development and implementation of low-carbon industrial processes, designs, and materials. By merging continuous improvement techniques with AI, Carbon Re's cloud-based platform aims to enhance operational efficiencies while significantly reducing greenhouse gas emissions, electricity consumption, and fuel costs in manufacturing. This innovative approach positions Carbon Re as a key player in the effort to drive substantial reductions in carbon emissions across foundational industries.

Cheesecake Energy specializes in the development of advanced thermal and compressed air energy systems that facilitate the storage of energy from intermittent renewable sources. By converting this stored energy into reliable power on demand, the company addresses the challenges associated with renewable energy variability. Cheesecake Energy's technology employs a combination of compressed air and thermal energy storage, utilizing industrial components that are readily available in the market. This approach not only enhances the durability of the storage systems but also allows clients to acquire these devices at a competitive price, making renewable energy more accessible and dependable.

PetMedix Ltd is a veterinary biopharmaceutical company based in Cambridge, United Kingdom, focused on developing therapeutic antibody drugs for pets. Founded in 2017, the company utilizes advanced scientific methods to create innovative therapies that enhance the health and well-being of companion animals. PetMedix offers specialized platforms, including the Ky9 and Felyne transgenic mouse systems, which are designed to produce high-quality, therapeutic antibodies tailored specifically for pets. By leveraging over thirty years of expertise in drug development, PetMedix aims to provide effective medical solutions that meet the unique needs of animals, ensuring they receive appropriate care and treatment.

Helio Display Materials specializes in developing innovative perovskite-based materials designed to enhance the performance and efficiency of display technologies. By utilizing metal halide perovskites, the company creates materials that enable displays to produce richer and more vibrant colors while consuming significantly less power. Helio's mission focuses on improving the overall visual experience, making displays brighter and more colorful. The company is committed to advancing research and development in this field by collaborating with scientific and industry experts, ensuring a strong intellectual property foundation rooted in scientific principles. Through its groundbreaking materials, Helio aims to revolutionize the display industry, particularly for televisions and other visual technologies.

Nozzle.ai is an eCommerce and advertising optimization platform for Amazon. Nozzle.ai delivers direct-to-consumer level insights about customers on Amazon to beat the competition and grow businesses. Nozzle.ai aims to simplify the selling experience on Amazon.

Nyobolt is a developer of advanced battery technology focused on automotive applications. Founded in 2020 and based in Cambridge, United Kingdom, the company specializes in creating batteries that offer high power, rapid charging capabilities, and substantial energy storage. By utilizing innovative materials, efficient cell designs, and sophisticated software control, Nyobolt aims to provide the automotive industry with solutions tailored for high-power usage. Its research and development efforts are directed toward enhancing battery performance to meet the growing demands of electric vehicles and other automotive technologies.

Echion Technologies Ltd. is a company based in Cambridge, United Kingdom, founded in 2017, that specializes in the development and manufacturing of advanced materials for lithium-ion batteries. The company focuses on producing optimized anode materials, notably its proprietary XNO® material, which enhances charging speed, extends battery lifespan, and improves safety compared to conventional options. Echion aims to serve the mobile device and automotive industries, particularly targeting the heavy-duty electric vehicle market. By offering cost-effective battery electrode materials, Echion strives to promote sustainable electrification and improve efficiency within the transportation sector.

Bonnet Ltd. is a London-based company founded in 2019 that specializes in a charging-as-a-service platform for electric vehicle drivers. The company addresses the challenges faced by drivers who must register separately for multiple public charging networks by offering a single app that enables access to any public charger. This streamlined service caters to both individual drivers and businesses, simplifying the charging process and enhancing the overall user experience for electric vehicle owners.

Arkivum specializes in long-term data management and digital preservation, catering to organizations in data-intensive and regulated markets worldwide. The company offers cloud-based software and services that ensure data remains secure, accessible, and usable over time, addressing the needs of clients who require reliable data storage solutions. Arkivum emphasizes data integrity and provides expert guidance on compliance with evolving regulatory requirements. Its vendor-neutral technology allows clients to retain ownership of their data, avoiding lock-in with any single provider. By focusing on effective data archiving and preservation, Arkivum enables organizations to maintain the value of their data while meeting complex compliance standards.

Fresh Check is a simple sticker that you put inside the packaging of food that changes colour when your food has actually gone off, not when the use-by date says so.

Oxford Endovascular is focused on developing an innovative medical device for the treatment of brain aneurysms. The company's technology employs a laser-cut metal alloy with shape-memory properties, which can be inserted into a patient's brain via a catheter. Once in place, the device expands into a tiny mesh tube, known as a flow diverter, that conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, facilitating its healing and reducing the risk of rupture. By utilizing advanced origami engineering, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for those affected by intracranial aneurysms.

Porotech is a spin-out from the University of Cambridge that specializes in the development of gallium nitride (GaN) semiconductor technologies. Co-founded by Dr. Tongtong Zhu, Dr. Yingjun Liu, and Prof. Rachel Oliver, the company focuses on creating energy-efficient wide-bandgap semiconductors through advanced material technologies. By harnessing the potential of GaN, Porotech aims to enhance the efficiency of light-emitting diodes and various electronic devices, thereby contributing to innovations in the electronics industry.

Versed AI helps companies to monitor, manage, and mitigate supply chain risks and identify constituents of their supply chains. It is through using cutting-edge natural language processing (NLP) techniques and Machine Learning (ML) to extract buyer-supplier relationships from text documents and aggregate this into a large supply chain map. It is founded by Simon Baker and Fenelle Boyle.

Mach42 is a University of Oxford spin-out commercializing new machine learning technology. We leverage proprietary neural network technology to accelerate expensive calculations — and we do it with minimal data and 99.9% fidelity.

Mogrify has developed a proprietary suite of technologies aimed at advancing patient care through innovative in vivo reprogramming therapies. The company's platforms, MOGRIFY and epiMOGRIFY, utilize a systematic big-data approach to direct cellular reprogramming, leveraging next-generation sequencing and gene regulatory data to predict the necessary transcription and growth factors for generating any target human cell type from various sources. This technology enhances existing stem cell programming methods or allows for direct transdifferentiation between mature cell types. Mogrify focuses on creating functional cell types for applications in ophthalmology, otology, and other degenerative diseases, addressing critical challenges related to efficacy, safety, and scalability in cell therapy. Positioned within a regenerative medicine market projected to reach $150 billion by 2028, Mogrify is commercializing its technology through in vivo therapy development, co-development partnerships, and exploration of additional therapeutic and non-therapeutic applications.

iKVA is a company that specializes in AI-powered knowledge management solutions. Its platform is designed to help organizations discover and transform data into actionable business insights. By employing machine learning, natural language processing, and semantic technology, iKVA indexes unstructured data from various sources, such as document archives, emails, chats, and videos. This capability significantly reduces the time businesses spend searching for information and mitigates risks by ensuring that the correct information is readily available.

Zentraxa is a developer of biopolymers focused on advancing medical processes and functions. Utilizing its proprietary technological platform, Zentide, the company specializes in the design, production, and testing of complex novel peptides. This innovative platform enables Zentraxa to overcome traditional bio-design limitations associated with conventional peptide synthesis, employing a universal process that enhances efficiency and versatility. Additionally, Zentraxa's unique manufacturing techniques facilitate the creation of biological adhesives, providing valuable support for various research and development initiatives in the medical field.

Abselion specializes in the development of biological sensors aimed at the rapid and cost-effective detection of various biological substances, including proteins, DNA, and small molecules. The company's innovative diagnostic analyzers and kits simplify the analysis of these biomolecules, making them valuable tools for pharmaceutical research and manufacturing. By enabling researchers to conduct sensitive, rapid, and near real-time medical diagnoses, Abselion enhances the understanding of biomolecular interactions, particularly in protein interaction analysis. This focus on efficiency and accuracy positions Abselion as a key player in the field of biosensing technology.

Oxford Endovascular is focused on developing an innovative medical device for the treatment of brain aneurysms. The company's technology employs a laser-cut metal alloy with shape-memory properties, which can be inserted into a patient's brain via a catheter. Once in place, the device expands into a tiny mesh tube, known as a flow diverter, that conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, facilitating its healing and reducing the risk of rupture. By utilizing advanced origami engineering, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for those affected by intracranial aneurysms.

GripAble Ltd. designs and develops digital therapy devices aimed at improving rehabilitation for individuals with movement impairments such as stroke, arthritis, cerebral palsy, and trauma. Founded in 2017 and based in London, the company offers a portable, wireless handgrip device that connects to a mobile application. This application allows users to engage with therapy games while providing assessment and training for hand and arm functions. GripAble's innovative approach focuses on making therapy more accessible and engaging for patients, enabling them to practice essential daily tasks in a fun and motivating way. By combining hardware and software, GripAble addresses the needs of over 500 million people worldwide who face challenges with arm mobility, facilitating self-training both in clinical settings and at home.

PhoreMost Limited is a drug discovery company based in Cambridge, United Kingdom, focused on identifying new druggable targets for cancer and other unmet diseases. Since its incorporation in 2014, the company has developed Site-Seeker, a platform that uncovers cryptic druggable sites within the human genome and connects them to therapeutic functions in live-cell contexts. This innovative approach allows PhoreMost to design small molecule drugs based on functionally validated protein fragments. By collaborating with a global network of academic and industrial partners, the company aims to bring novel targeted therapies to market more efficiently, ultimately benefiting patients through cost savings and the development of first-in-class drug discovery programs for potential licensing to pharmaceutical companies.

Riverlane is a business focused on developing quantum computing software and engineering instruments to enhance the performance of quantum computers. The company collaborates with quantum computer manufacturers to create essential hardware and software tools that address the challenges posed by unstable qubits and system defects. By designing an ultra-low latency quantum operating system, Riverlane accelerates quantum-classical hybrid algorithms, thereby advancing hardware research and development. Their algorithms are specifically engineered to optimize the utilization of the complete quantum computing stack, helping hardware partners mitigate the system errors that currently hinder the effectiveness of quantum computers. Through these innovative solutions, Riverlane aims to transform experimental quantum technologies into viable commercial products.

Cytoseek Limited, a spinout from the University of Bristol, develops innovative cell therapies aimed at treating cancer, heart disease, osteoarthritis, and diabetic wound healing. Established in 2017 and based in Bristol, the company utilizes a novel cell membrane augmentation technology that enhances the functionality of cell therapies. This technology enables targeted tissue delivery and improves cell survivability, potentially increasing the efficacy of treatments. Cytoseek is currently conducting proof of principle studies to validate its approach and is actively seeking partnerships with other cell therapy companies to advance these therapies into clinical applications, ultimately striving to improve human health.

TextMine is a developer of an AI-powered knowledge base designed to manage and streamline business-critical documents, including invoices, payslips, tender documents, compliance reports, and contracts. Utilizing patented knowledge graph technology, the platform enhances the usability and searchability of contract data, consolidating information into a single operational layer. This approach facilitates proactive decision-making and improves data transparency, allowing for more scalable and uniform document creation. By implementing TextMine's solutions, organizations can achieve significant savings in time and costs while minimizing risk and enhancing compliance.